Q1 2027 Medtronic PLC Earnings Call Transcript
Key Points
- Medtronic PLC (MDT) delivered a strong fiscal Q1 2027 with revenue of $9.8 billion and adjusted EPS of $1.45, both well ahead of expectations, driven by 13.7% organic revenue growth.
- The company's Cardiac Ablation Solutions (CAS) business continues to outperform, delivering 88% worldwide growth and surpassing the $2 billion trailing 12-month revenue mark ahead of schedule, with a 9-point increase in US share.
- Medtronic PLC (MDT) is seeing broad-based strength across its largest businesses, with Cardiac Rhythm Management (CRM) growing 15%, Cranial and Spinal Technologies (CST) up 13%, and Surgical up 9%, demonstrating the durability of its growth.
- The company is making significant progress in its next cycle of growth platforms, including Symplicity (renal denervation), Altaviva (pelvic health), and Hugo (robotic surgery), all showing strong momentum and early adoption.
- Medtronic PLC (MDT) raised its full-year fiscal 2027 organic revenue growth guidance to 7.25%-7.75%, a 50 basis point increase, reflecting confidence in continued strong performance and execution.
- The company is strategically deploying capital to enhance its portfolio, including a $700 million investment in Cornerstone Robotics and an investment in Pi-Cardia, expanding its reach in high-growth markets like soft tissue robotics and structural heart.
- Medtronic PLC (MDT)'s Q1 results were significantly boosted by an extra selling week, contributing approximately $570 million or 670 basis points to organic growth, which may not be repeatable in subsequent quarters.
- The company faces ongoing gross margin headwinds from unfavorable business mix, particularly from the fast-growing Diabetes and CAS businesses, which are lower margin and continue to pressure overall profitability.
- Medtronic PLC (MDT) expects foreign exchange to be a headwind for the full year, with a projected $50 million to $150 million negative impact on revenue, potentially dampening reported growth.
- The Neuromodulation business saw only 3% growth globally, impacted by softness in the SCS market and replacement headwinds in DBS, indicating challenges in certain legacy product lines.
- The company's guidance for Q2 implies a significant slowdown to roughly 6% organic revenue growth, suggesting that the exceptional Q1 performance may not be sustained in the near term.
- Medtronic PLC (MDT) is making significant investments in acquisitions and commercial expansion, which are expected to create near-term pressure on operating margins and EPS, as evidenced by the slight reduction in full-year operating margin expansion guidance.
(video playing) Good morning, and welcome to our fiscal '27 first quarter earnings webcast. I'm Ingrid Goldberg, Head of Medtronic Investor Relations. And I'm joined by Geoff Martha, Chairman and Chief Executive Officer; and Thierry Pieton, Chief Financial Officer. Geoff and Thierry will provide comments on the results of our first quarter which ended on July 31, 2026, and our outlook for the remainder of the fiscal year '27. After our prepared remarks, we'll take questions from the sell-side analysts that cover the company.
Earlier this morning, we issued a press release discussing our quarterly results and several financial schedules. We also posted an earnings presentation that provides additional details on our performance. The presentation can be accessed in our earnings press release or on our website at investorrelations.medtronic.com. During today's program many of our statements will be forward-looking and actual results may differ materially as explained in our SEC filings. We undertake no obligation to update any forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
